316 related articles for article (PubMed ID: 30592275)
41. Pain and genetics.
Fernandez Robles CR; Degnan M; Candiotti KA
Curr Opin Anaesthesiol; 2012 Aug; 25(4):444-9. PubMed ID: 22732422
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the Effects of OPRM1 A118G Polymorphism Using Different Opioids: A Prospective Study.
Takemura M; Niki K; Okamoto Y; Kawamura T; Kohno M; Matsuda Y; Ikeda K
J Pain Symptom Manage; 2024 Jan; 67(1):39-49.e5. PubMed ID: 37757956
[TBL] [Abstract][Full Text] [Related]
43. Chronic pain after lower abdominal surgery: do catechol-O-methyl transferase/opioid receptor μ-1 polymorphisms contribute?
Kolesnikov Y; Gabovits B; Levin A; Veske A; Qin L; Dai F; Belfer I
Mol Pain; 2013 Apr; 9():19. PubMed ID: 23566343
[TBL] [Abstract][Full Text] [Related]
44. Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement.
Matic M; Jongen JL; Elens L; de Wildt SN; Tibboel D; Sillevis Smitt PA; van Schaik RH
Pharmacogenomics; 2017 Aug; 18(12):1133-1142. PubMed ID: 28745577
[TBL] [Abstract][Full Text] [Related]
45. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis.
Ren ZY; Xu XQ; Bao YP; He J; Shi L; Deng JH; Gao XJ; Tang HL; Wang YM; Lu L
Pain Physician; 2015; 18(2):131-52. PubMed ID: 25794200
[TBL] [Abstract][Full Text] [Related]
46. OPRM1 rs1799971, COMT rs4680, and FAAH rs324420 genes interact with placebo procedures to induce hypoalgesia.
Colloca L; Wang Y; Martinez PE; Chang YC; Ryan KA; Hodgkinson C; Goldman D; Dorsey SG
Pain; 2019 Aug; 160(8):1824-1834. PubMed ID: 31335650
[TBL] [Abstract][Full Text] [Related]
47. Innate Immune and Neuronal Genetic Markers Are Highly Predictive of Postoperative Pain and Morphine Patient-Controlled Analgesia Requirements in Indian but Not Chinese or Malay Hysterectomy Patients.
Barratt DT; Sia AT; Tan EC; Somogyi AA
Pain Med; 2021 Nov; 22(11):2648-2660. PubMed ID: 34015137
[TBL] [Abstract][Full Text] [Related]
48. Molecular Basis of Cancer Pain Management: An Updated Review.
V Subramaniam A; Salem Yehya AH; Oon CE
Medicina (Kaunas); 2019 Sep; 55(9):. PubMed ID: 31547335
[TBL] [Abstract][Full Text] [Related]
49. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease.
Klepstad P; Rakvåg TT; Kaasa S; Holthe M; Dale O; Borchgrevink PC; Baar C; Vikan T; Krokan HE; Skorpen F
Acta Anaesthesiol Scand; 2004 Nov; 48(10):1232-9. PubMed ID: 15504181
[TBL] [Abstract][Full Text] [Related]
50. Review of Opioid Pharmacogenetics and Considerations for Pain Management.
Owusu Obeng A; Hamadeh I; Smith M
Pharmacotherapy; 2017 Sep; 37(9):1105-1121. PubMed ID: 28699646
[TBL] [Abstract][Full Text] [Related]
51. Current evidence for a genetic modulation of the response to analgesics.
Lötsch J; Geisslinger G
Pain; 2006 Mar; 121(1-2):1-5. PubMed ID: 16472919
[No Abstract] [Full Text] [Related]
52. Effect of genetic factors on opioid action.
Kosarac B; Fox AA; Collard CD
Curr Opin Anaesthesiol; 2009 Aug; 22(4):476-82. PubMed ID: 19502975
[TBL] [Abstract][Full Text] [Related]
53. Pharmacogenetics in pain management: the clinical need.
Webster LR
Clin Lab Med; 2008 Dec; 28(4):569-79. PubMed ID: 19059063
[TBL] [Abstract][Full Text] [Related]
54. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
55. Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain.
Gong XD; Wang JY; Liu F; Yuan HH; Zhang WY; Guo YH; Jiang B
Asian Pac J Cancer Prev; 2013; 14(5):2937-43. PubMed ID: 23803057
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenomics in Pain Management.
Saba R; Kaye AD; Urman RD
Anesthesiol Clin; 2017 Jun; 35(2):295-304. PubMed ID: 28526150
[TBL] [Abstract][Full Text] [Related]
57. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
58. Can heterogeneity of chronic sickle-cell disease pain be explained by genomics? A literature review.
Adegbola MA
Biol Res Nurs; 2009 Jul; 11(1):81-97. PubMed ID: 19487302
[TBL] [Abstract][Full Text] [Related]
59. Pilot study examining the frequency of several gene polymorphisms involved in morphine pharmacodynamics and pharmacokinetics in a morbidly obese population.
Lloret Linares C; Hajj A; Poitou C; Simoneau G; Clement K; Laplanche JL; Lépine JP; Bergmann JF; Mouly S; Peoc'h K
Obes Surg; 2011 Aug; 21(8):1257-64. PubMed ID: 20411349
[TBL] [Abstract][Full Text] [Related]
60. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects.
Kolesnikov Y; Gabovits B; Levin A; Voiko E; Veske A
Anesth Analg; 2011 Feb; 112(2):448-53. PubMed ID: 21127283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
